Marker Therapeutics, Inc.

Monthly Archives: March 2015

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors. David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products.
Read More

TapImmune Receives $1,000,000 from Strategic Investor

Investment bolsters immediate capital needs for progressing clinical programs SEATTLE, March 10, 2015 – TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.
Read More